312 related articles for article (PubMed ID: 36830114)
1. Three Innovations of Next-Generation Antibiotics: Evolvability, Specificity, and Non-Immunogenicity.
Shim H
Antibiotics (Basel); 2023 Jan; 12(2):. PubMed ID: 36830114
[TBL] [Abstract][Full Text] [Related]
2. Leveraging Marine Natural Products as a Platform to Tackle Bacterial Resistance and Persistence.
Valdes-Pena MA; Massaro NP; Lin YC; Pierce JG
Acc Chem Res; 2021 Apr; 54(8):1866-1877. PubMed ID: 33733746
[TBL] [Abstract][Full Text] [Related]
3. Returning to Nature for the Next Generation of Antimicrobial Therapeutics.
MacNair CR; Tsai CN; Rutherford ST; Tan MW
Antibiotics (Basel); 2023 Aug; 12(8):. PubMed ID: 37627687
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic resistant bacteria: current situation and treatment options to accelerate the development of a new antimicrobial arsenal.
Tarín-Pelló A; Suay-García B; Pérez-Gracia MT
Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1095-1108. PubMed ID: 35576494
[TBL] [Abstract][Full Text] [Related]
5. Non-traditional approaches for control of antibiotic resistance.
Umarje SC; Banerjee SK
Expert Opin Biol Ther; 2023; 23(11):1113-1135. PubMed ID: 38007617
[TBL] [Abstract][Full Text] [Related]
6. Resistance-proof antimicrobial drug discovery to combat global antimicrobial resistance threat.
Upadhayay A; Ling J; Pal D; Xie Y; Ping FF; Kumar A
Drug Resist Updat; 2023 Jan; 66():100890. PubMed ID: 36455341
[TBL] [Abstract][Full Text] [Related]
7. Role of Antimicrobial Drug in the Development of Potential Therapeutics.
Mayegowda SB; Ng M; Alghamdi S; Atwah B; Alhindi Z; Islam F
Evid Based Complement Alternat Med; 2022; 2022():2500613. PubMed ID: 35571735
[TBL] [Abstract][Full Text] [Related]
8. Novel Strategies to Combat the Emerging Drug Resistance in Human Pathogenic Microbes.
Qadri H; Shah AH; Mir M
Curr Drug Targets; 2021; 22(12):1424-1436. PubMed ID: 33371847
[TBL] [Abstract][Full Text] [Related]
9. Emerging Non-Traditional Approaches to Combat Antibiotic Resistance.
Konwar AN; Hazarika SN; Bharadwaj P; Thakur D
Curr Microbiol; 2022 Sep; 79(11):330. PubMed ID: 36155858
[TBL] [Abstract][Full Text] [Related]
10. Short Antimicrobial Peptides.
Sharma K; Aaghaz S; Shenmar K; Jain R
Recent Pat Antiinfect Drug Discov; 2018; 13(1):12-52. PubMed ID: 29952266
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects.
Uddin TM; Chakraborty AJ; Khusro A; Zidan BRM; Mitra S; Emran TB; Dhama K; Ripon MKH; Gajdács M; Sahibzada MUK; Hossain MJ; Koirala N
J Infect Public Health; 2021 Dec; 14(12):1750-1766. PubMed ID: 34756812
[TBL] [Abstract][Full Text] [Related]
12. Bacterial Resistance: Antibiotics of Last Generation used in Clinical Practice and the Arise of Natural Products as New Therapeutic Alternatives.
Corrêa RCG; Heleno SA; Alves MJ; Ferreira ICFR
Curr Pharm Des; 2020; 26(8):815-837. PubMed ID: 32091328
[TBL] [Abstract][Full Text] [Related]
13. Innovative Biomedical and Technological Strategies for the Control of Bacterial Growth and Infections.
Matias LLR; Damasceno KSFDSC; Pereira AS; Passos TS; Morais AHA
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255281
[TBL] [Abstract][Full Text] [Related]
14. The Impending Renaissance in Discovery & Development of Natural Products.
Pawar SV; Ho JC; Yadav GD; Yadav VG
Curr Top Med Chem; 2017; 17(2):251-267. PubMed ID: 27237327
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial Peptides: the Achilles' Heel of Antibiotic Resistance?
Lewies A; Du Plessis LH; Wentzel JF
Probiotics Antimicrob Proteins; 2019 Jun; 11(2):370-381. PubMed ID: 30229514
[TBL] [Abstract][Full Text] [Related]
16. Harnessing the CRISPR-Cas Systems to Combat Antimicrobial Resistance.
Duan C; Cao H; Zhang LH; Xu Z
Front Microbiol; 2021; 12():716064. PubMed ID: 34489905
[TBL] [Abstract][Full Text] [Related]
17. Role of Nutrients and Phyto-compounds in the Modulation of Antimicrobial Resistance.
Harakeh S; Khan I; Almasaudi SB; Azhar EI; Al-Jaouni S; Niedzweicki A
Curr Drug Metab; 2017; 18(9):858-867. PubMed ID: 28721833
[TBL] [Abstract][Full Text] [Related]
18. The Advantages and Challenges of Using Endolysins in a Clinical Setting.
Murray E; Draper LA; Ross RP; Hill C
Viruses; 2021 Apr; 13(4):. PubMed ID: 33920965
[TBL] [Abstract][Full Text] [Related]
19. The Neutrally Charged Diarylurea Compound PQ401 Kills Antibiotic-Resistant and Antibiotic-Tolerant Staphylococcus aureus.
Kim W; Zou G; Pan W; Fricke N; Faizi HA; Kim SM; Khader R; Li S; Lee K; Escorba I; Vlahovska PM; Gao H; Ausubel FM; Mylonakis E
mBio; 2020 Jun; 11(3):. PubMed ID: 32605985
[TBL] [Abstract][Full Text] [Related]
20. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model.
Brogan DM; Mossialos E
Global Health; 2013 Nov; 9():58. PubMed ID: 24199835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
